The biopharma industry outlook on 2026: Optimism and tension
A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.
⚠️ 风险分析 中
摘要：中国生物制药企业竞争加剧，可能影响美国行业复苏，并面临监管不确定性。
影响：中国生物制药企业的激烈竞争可能对美国同行的市场复苏构成压力，同时行业整体面临监管动荡风险。
建议：关注中美生物制药领域监管动态，评估市场竞争格局，加强合规与风险管理。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.